Enzolytics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENZC research report →
Companyenzolytics.com
Enzolytics, Inc. , a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.
- CEO
- Steven Sharabura
- IPO
- 2009
- Employees
- 1
- HQ
- Plano, TX, US
Price Chart
Valuation
- Market Cap
- $2.36M
- P/E
- -5.55
- P/S
- 0.00
- P/B
- -0.02
- EV/EBITDA
- -10.24
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.31%
- ROIC
- 0.29%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-92,239 · 76.59%
- EPS
- $0.00 · 100.00%
- Op Income
- $-82,983
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.24
- Avg Volume
- 11.62M
Get TickerSpark's AI analysis on ENZC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ENZC Coverage
We haven't published any research on ENZC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ENZC Report →